delgocitinib
delgocitinib is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Anzupgo. Available dosage form: cream.
Drug Details
- Generic Name
- delgocitinib
- Brand Names
- Anzupgo
- Application Number
- NDA219155
- Sponsor
- LEO Pharma, Inc
- NDC Codes
- 2
- Dosage Forms
- CREAM
- Routes
- TOPICAL
- Active Ingredients
- DELGOCITINIB
Indications and Usage
1 INDICATIONS AND USAGE ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ( 1 ) Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended.